Investment
Features
FeesSafety
Academy
More
Pluang+

Fortitude names Jaime Leverton CEO ahead of Nasdaq listing via HeartSciences merger

Market News
17 Sep 2026
Coindesk
View Source
Bullish
Fortitude names Jaime Leverton CEO ahead of Nasdaq listing via HeartSciences merger

Fortitude Mining Holdings appointed Jaime Leverton, former Hut 8 CEO, as its new CEO as it prepares for a Nasdaq listing through a merger with HeartSciences. Leverton will take over on September 21, with Andrea Childs moving to COO. The combined company is expected to be valued at around $400 million and will trade under the ticker 'TUDE'. Fortitude, focused on mining Zcash, produced about 28% of all ZEC mined in the first half of 2026 and reported $20.9 million in Q2 revenue. The merger is expected to close in Q4, pending shareholder approval.

The story about Fortitude Mining Holdings' new CEO Jaime Leverton is presented with market context from Pluang's platform. As of September 17, 2026, 44 out of 50 major cryptocurrencies on Pluang rose while 5 fell. Notable price changes include LUNC at Rp0,885 with a 4.71% increase and a typical hold time of 193 days, LTC at Rp939.378 with a 4.51% increase and a hold time of 77 days, and EGLD at Rp70.119 with a 4.40% increase and a hold time of 84 days.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
1 hour ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
2 hours ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
3 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App